Primary Care’s Role in Skin Cancer Detection

Expert panelists discuss the essential role of primary care in early skin cancer detection, balancing clinical judgment with emerging AI artificial intelligence tools, and more.

Aprocitentan Reduces Blood Pressure in Black Adults with Resistant HTN: Daily Dose
May 09, 2025

Your daily dose of the clinical news you may have missed.

Single Afternoon Dose of ICS Linked to Better Lung Function and Reduced Inflammation in Asthma
May 08, 2025

The chronotherapeutic approach aligns treatment with peak glucocorticoid sensitivity, so may mitigate onset of the inflammatory cascade that triggers nocturnal exacerbations.

Rising Lp(a) Levels Increase Risk of Subsequent CVD Events in Adults with ASCVD, According to Large Real-World Study
May 08, 2025

Any increase in lipoprotein(a) levels was linked to increased risk of myocardial infarction and stroke; women and Black adults are most likely to be affected.

Understanding Gaps in Patient Knowledge of Cervical Cancer Screening
May 08, 2025

An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences.

FDA Greenlights Low-Dose Clorthalidone (12.5 mg) for Treatment of Hypertension in Adults
May 08, 2025

Low-dose clorthalidone offers clinicians a new option for initiating treatment that may mitigate well-known metabolic adverse effects.

GLP-1 Agonists May Preserve Muscle Mass During Weight Loss: Daily Dose
May 08, 2025

Your daily dose of the clinical news you may have missed.

Roflumilast Foam 0.3% Update: Pivotal Phase 3 Trial Outcomes Published in JAMA Dermatology, Arcutis Announces
May 08, 2025

Publication of the phase 3 ARRECTOR trial findings precede an anticipated PDUFA date of May 22, 2025, for the investigational foam, now under FDA review.

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians
May 07, 2025

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

Machine Learning Model Effectively Predicts Depression Risk in Adults with COPD
May 07, 2025

The model demonstrated 70.63% accuracy for predicting depression, a common comorbidity seen in COPD and one that increases risk for negative outcomes.

Investigational GPR119 Agonist Shows Dual Hepatoprotective and Glycemic Benefits in MASH Patients
May 07, 2025

EASL 2025. DA-1241 significantly reduced plasma ALT levels, improved systemic inflammatory and fibrosis biomarkers, according to drug developer MetaVia.